Keywords: Bardoxolone, Kidney disease, Diabetes, Reata, Kyowa Hakko Kirin, Licensing

Reata Pharma licenses CKD drug bardoxolone to Kyowa Hakko Kirin in $272 million deal for Asian territories

Article | 08 January 2010

Print This

US drug developer Reata Pharmaceuticals has entered into a licensing agreement that provides Japan’s Kyowa Hakko Kirin with the ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in